ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0449

Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca

Blake Warner1, Billel Gasmi2, David Kleiner3, Paola Perez Riveros4, Daniel Barber5, Shunsuke Sakai5 and Alan Baer6, 1National Institute of Dental and Craniofacial Research, Bethesda, 2National Cancer Institute, Bethesda, MD, 3National Cancer Institute, Bethesda, 4National Institute of Dental and Craniofacial Research, Bethesda, MD, 5National Institute of Allergy and Infectious Disease, Bethesda, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2020

Keywords: Cytotoxic Cells, immunology, Inflammation, Sjögren's Syndrome, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Immunological Complications of Therapy (0449–0453)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune response. However, ICI can elicit inflammatory reactions termed immune-related adverse events (irAEs). We previously reported that ICI therapy is associated an abrupt onset, oftentimes severe irAE resembling Sjögren’s syndrome (Warner et al., 2019). Herein we aimed to characterize the inflammatory infiltrate of labial salivary gland biopsies (LSGB) from patients with ICI sicca.

Methods: Patients with ICI sicca (ICI, n=21) and healthy volunteers (HV, n=9) underwent saliva assessments, medical workup, and LSGBs. We measured the surface area of acini and fibrosis with histochemical stains and the density of IHC stains in LSGB using QuPath_2.0. Transcriptional profiling of immune markers was determined using RNA sequencing. Dissociated LSGB were subjected to 4h PMA/ionomycin stimulation and subsequent flow cytometry analysis. In patients with available dissociated tissues, single cell (sc)RNA sequencing was performed. 

Results: LSGB form ICI sicca patients demonstrated architectural distortion including the most common findings of reduced density of acini (p=0.01), variable fibrosis (p= 0.07), and mild-to-severe sialadenitis composed chiefly of T lymphocytes. In some patients, destruction of PD-L1+ epithelia with marked effacement of gland architecture was observed. IHC demonstrated the ICI inflammatory infiltrate was composed increased numbers of CD8+ (p=0.039), CD4+ (p=0.078), and CD3+ (p=0.05) T lymphocytes. RNA sequencing exhibited significantly higher PD-1 expression in the ICI LSGB (p=0.02) with higher CD8 and CD39 expression (p=0.05). CD3, CD4, 4-1BB, TIM3, GzmB, FOXP3 and PDL1 were all upregulated in the ICI group but did not reach statistical significance. Flow cytometry confirmed increased infiltration with CD3+ with significant increases in activated cytotoxic T cells (CD8+CD107a+). scRNAseq and confocal immunofluorescence microscopy confirmed increased density of CD8+PD-1+CD39+ T cells in the ICI LSGB.

Conclusion: The histopathology of ICI induced sialadenitis consists primarily of a T cell infiltrate with parenchymal destruction with patchy fibrosis. IHC analysis combined with the transcriptional data show the presence of cytotoxic T-cell population (CD8, 4-1BB, TIM3, GrzB) with a chronic antigen exposure phenotype (PD-1, CD39). Further investigation is necessary to determine if this T-cell population is causing the sicca or if it constitutes a reactive population.

Example of severe sialadenitis induced by anti-PD-L1 therapy . Total effacement of the gland architecture with injury to the acini and ducts is evident. The infiltrate is composed chiefly of T cells without B cells. CD4 cells predominate, although infiltration of the acini and ducts is seen.


Disclosure: B. Warner, None; B. Gasmi, None; D. Kleiner, None; P. Perez Riveros, None; D. Barber, None; S. Sakai, None; A. Baer, Bristol Myers Squibb, 5, Sanofi, 5.

To cite this abstract in AMA style:

Warner B, Gasmi B, Kleiner D, Perez Riveros P, Barber D, Sakai S, Baer A. Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/cytotoxic-t-cells-with-a-chronic-antigen-exposure-phenotype-drive-immune-checkpoint-inhibitor-sicca/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytotoxic-t-cells-with-a-chronic-antigen-exposure-phenotype-drive-immune-checkpoint-inhibitor-sicca/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology